Equities research analysts predict that Natus Medical Inc (NASDAQ:BABY) will report $130.61 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Natus Medical’s earnings, with the highest sales estimate coming in at $130.80 million and the lowest estimate coming in at $130.40 million. Natus Medical reported sales of $122.23 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 6.9%. The business is expected to issue its next earnings results before the market opens on Wednesday, July 25th.
According to Zacks, analysts expect that Natus Medical will report full year sales of $537.36 million for the current year, with estimates ranging from $536.30 million to $538.18 million. For the next fiscal year, analysts forecast that the business will post sales of $557.44 million per share, with estimates ranging from $546.90 million to $566.63 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Natus Medical.
Natus Medical (NASDAQ:BABY) last issued its earnings results on Wednesday, April 25th. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.24. Natus Medical had a positive return on equity of 10.96% and a negative net margin of 4.71%. The business had revenue of $128.60 million during the quarter, compared to analysts’ expectations of $125.91 million. During the same period in the prior year, the firm posted $0.30 EPS. Natus Medical’s quarterly revenue was up 3.1% compared to the same quarter last year.
A number of equities research analysts recently weighed in on the company. BidaskClub raised Natus Medical from a “hold” rating to a “buy” rating in a report on Saturday, April 21st. Zacks Investment Research raised Natus Medical from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 10th. Finally, ValuEngine cut Natus Medical from a “hold” rating to a “sell” rating in a report on Thursday, May 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $44.33.
In other news, VP Dong Chune Christopher Chung sold 15,358 shares of Natus Medical stock in a transaction on Monday, May 7th. The stock was sold at an average price of $33.32, for a total value of $511,728.56. Following the completion of the sale, the vice president now directly owns 151,731 shares of the company’s stock, valued at approximately $5,055,676.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William M. Moore sold 8,000 shares of Natus Medical stock in a transaction on Wednesday, May 16th. The shares were sold at an average price of $35.91, for a total value of $287,280.00. Following the completion of the sale, the director now directly owns 30,410 shares of the company’s stock, valued at $1,092,023.10. The disclosure for this sale can be found here. Insiders have sold a total of 183,358 shares of company stock valued at $6,154,209 over the last ninety days. Insiders own 5.50% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in BABY. SG Americas Securities LLC acquired a new stake in shares of Natus Medical in the 1st quarter valued at $124,000. US Bancorp DE boosted its position in shares of Natus Medical by 81.2% in the 1st quarter. US Bancorp DE now owns 4,742 shares of the medical equipment provider’s stock worth $159,000 after purchasing an additional 2,125 shares during the last quarter. Elkfork Partners LLC bought a new position in shares of Natus Medical in the 4th quarter worth $163,000. Profund Advisors LLC bought a new position in shares of Natus Medical in the 1st quarter worth $218,000. Finally, Stone Ridge Asset Management LLC bought a new position in shares of Natus Medical in the 4th quarter worth $303,000. 89.20% of the stock is owned by institutional investors.
BABY stock traded down $0.85 during midday trading on Tuesday, reaching $34.50. 134,074 shares of the company’s stock traded hands, compared to its average volume of 259,607. Natus Medical has a 1-year low of $28.00 and a 1-year high of $43.60. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of 23.79 and a beta of 0.49. The company has a debt-to-equity ratio of 0.31, a current ratio of 3.06 and a quick ratio of 2.28.
Natus Medical Company Profile
Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.